Q-omics provides the consensus-scored FZD8 profile across patient tissues and cancer cell-line models. FZD8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FZD8 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FZD8 RNA expression shows 17,765 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where FZD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FZD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FZD8 survival associations across molecular data types. FZD8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FZD8 RNA expression–survival associations across cancer types. High FZD8 expression shows unfavorable associations in UVM, MESO, KIRP, ACC, SARC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FZD8 RNA expression.
This table summarizes FZD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FZD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FZD8 shows lower tumor expression in THCA, LUAD, KICH, BRCA, LUSC and KIRC. The THCA box plot shows higher FZD8 RNA expression in normal versus tumor tissue (log2 FC = −2.167, t-test p < 0.001).
This table shows molecular features associated with FZD8 in patient tissues and cancer cell lines. In patient samples, FZD8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FZD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
